Oral butyrate for mildly to moderately active Crohn's disease. (Q46753169)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Oral butyrate for mildly to moderately active Crohn's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Gino R Corazza

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Morera R

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Ciccocioppo R

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Cazzola P

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Gotti S

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Tinozzi FP

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Tinozzi S

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 November 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

789-794

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16225487%20AND%20SRC:MED&resulttype=core&format=json

The butyrate story: old wine in new bottles?

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02639.X

Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02639.X

The colonic epithelium in ulcerative colitis: an energy-deficiency disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02639.X

Butyrate enhances major histocompatibility complex class I, HLA-DR and ICAM-1 antigen expression on differentiated human intestinal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02639.X

Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02639.X

Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02639.X

Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02639.X

Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02639.X

Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02639.X